• Skip to main content
  • Skip to footer

Oklahoma Medical Research Foundation | OMRF

  • About
    • General Information
    • Disease Research
    • Training & Outreach
    • Events
    • Careers
    • Contact Us
  • Science
    • Scientist Directory
    • Research Programs
    • Research Centers
    • Core Facilities
    • Scientific Publications
    • Scientific Seminars
    • Technology Ventures
  • News
    • Media Resources
    • News Releases
    • Publications
    • On Your Health
    • Bodywork
  • Patients
    • Anti Aging Study
    • Lupus (SLE)
    • MBTPS1 Related Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjögren’s Disease
    • Osteoarthritis
    • Other Autoimmune Disorders
  • Donate
    • Donate Now
    • Ways to Give
    • Tax Credit
    • Planned Giving
    • Contact Philanthropy

Publication PMID: 34911705

Almeida-Brasil CC, Hanly JG, Urowitz M, Clarke AE, Ruiz-Irastorza G, Gordon C, Ramsey-Goldman R, Petri M, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken C, Isenberg D, Rahman A, Manzi S, Jacobsen S, Lim S, van Vollenhoven RF, Nived O, Jönsen A, Kamen DL, Aranow C, Sanchez-Guerrero J, Gladman DD, Fortin PR, Alarcón GS, Merrill JT, Kalunian K, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta MA, Bruce IN, Inanc M, Abrahamowicz M, Bernatsky S. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis, 2021 December, PMID: 34911705, PMCID: PMC8862090

Before Footer

Equal Opportunity Employer

Footer

  • Jobs
  • Directory
  • Donor Privacy Statement
  • Ethics Point
  • Intranet
Facebook Twitter Instagram Linkedin

Subscribe to OMRF News
  • Contact
  • Careers
  • Donor Privacy
  • Ethics Point
  • Intranet
OMRF Logo
OKLAHOMA MEDICAL RESEARCH FOUNDATION
825 NE 13th St.
Oklahoma City, OK 73104
(405) 271-6673
Charity navigatorUnited WayTop Workplace